Volume 8, Issue 13

Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

In this issue:

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.

Learning objectives:

  • Identify appropriate patients for the initiation of disease modifying anti-inflammatory therapy.
  • Summarize the potential benefits and risks, as reported in phase 2 studies, of triple combination CFTR modulator therapy.


Jennifer Taylor-Cousar, MD, MSCS
Jennifer Taylor-Cousar, MD, MSCS

Medical Director, Clinical Research Services
Co-Director and CF TDC Director, Adult CF Program
Interim Associate Vice President of Diversity, Equity and Inclusion
Professor, Departments of Internal Medicine and Pediatrics
Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine
National Jewish Health
Denver, CO

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 27, 2019
Expiration date: September 26, 2021